Zacks Investment Research
06 Jul 2026, 22:50 UTC · 2h ago
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Jul 2026, 22:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Adma Biologics currently holds a Zacks Rank of #5 (Strong Sell). — A 'Strong Sell' rating from a quantitative model typically signals a bearish outlook on near-term price performance.
-0.60The consensus EPS projection for Adma Biologics has decreased by 2.38% over the past 30 days. — Downward revisions in earnings estimates often precede negative price action as they suggest deteriorating business fundamentals.
-0.40Adma Biologics is expected to report quarterly earnings of $0.16 per share, representing year-over-year growth of 6.67%. — Positive growth in earnings is fundamentally bullish, though the modest rate may limit the impact.
+0.20Continue reading
6 related stories
Search tags
Adma Biologics' Forward P/E ratio of 10.91 is significantly lower than its industry average of 21.56. — A valuation discount relative to peers can suggest the stock is undervalued, though it may also reflect systemic risks.
Which stocks this story touches
The company is currently assigned a Zacks Rank of #5 (Strong Sell) and has seen a recent decrease in consensus EPS projections.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
